Literature DB >> 33819502

Changes in temperature management and outcome after out-of-hospital cardiac arrest in United Kingdom intensive care units following publication of the targeted temperature management trial.

J P Nolan1, I Orzechowska2, D A Harrison2, J Soar3, G D Perkins4, M Shankar-Hari5.   

Abstract

AIM: To investigate how the publication of the targeted temperature management (TTM) trial in December 2013 affected the trends in temperature management and outcome following admission to UK intensive care units (ICUs) after out-of-hospital cardiac arrest (OHCA).
METHODS: We used a national ICU database of 1,181,405 consecutive admissions to 235 adult ICUs. OHCA admissions mechanically ventilated in the first 24 h in the ICU were divided into a pre-TTM trial cohort of patients admitted before publication of the TTM trial (January 2010-December 2013) and post-TTM cohort of patients admitted after TTM trial publication (January 2014-December 2017). The primary outcome variables were lowest temperature in the first 24 h in ICU and survival to hospital discharge.
RESULTS: The lowest temperature recorded in the first-24 h of admission was significantly higher in the post-TTM cohort (n = 18,106) than in the pre-TTM cohort (n = 12,162) (mean 34.7 (±1.6) versus 33.6 °C (±1.8); absolute difference 1.12 °C (95% CI 1.08-1.16). The post-TTM cohort had a greater prevalence of fever (>38.0 °C) (24.8% vs 14.7%; (odds ratio (OR) 1.91 (95% CI 1.80-2.03); p < 0.001)) and higher unadjusted in-hospital mortality (63.7% vs 61.6%). In a multilevel model, accounting for time trend and including site as a random effect, neither the step change in acute hospital mortality following publication of the TTM trial result (OR 1.04, 95% CI 0.95-1.15; p = 0.37), nor the change in slope (from OR 1.00 per year, 95% CI 0.97-1.04, to 1.04 per year, 95% CI 1.02-1.07; p = 0.059), was statistically significant. Adjusted analyses were limited by the models' dependence on temperature and temperature-related variables.
CONCLUSIONS: The lowest temperature recorded in the first-24 h of admission in OHCA patients was higher in the post-TTM cohort compared with the pre-TTM cohort. There has been an increase in the proportion of patients with fever (>38 °C) in the first 24 h. Although crude mortality was slightly higher in the post-TTM cohort, an analysis accounting for time trend and variation between critical care units, found no significant change associated with the TTM publication.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Cardiac arrest; Post-cardiac arrest care; Targeted temperature management

Mesh:

Year:  2021        PMID: 33819502     DOI: 10.1016/j.resuscitation.2021.03.027

Source DB:  PubMed          Journal:  Resuscitation        ISSN: 0300-9572            Impact factor:   5.262


  5 in total

1.  The importance of ventilator settings and respiratory mechanics in patients resuscitated from cardiac arrest.

Authors:  Domenico L Grieco; Eduardo L V Costa; Jerry P Nolan
Journal:  Intensive Care Med       Date:  2022-07-01       Impact factor: 41.787

2.  Targeted Temperature Management in Unconscious Survivors of Postcardiac Arrest: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors:  Shakti Bedanta Mishra; Rupali Patnaik; Arun Rath; Samir Samal; Abhilash Dash; Biswajit Nayak
Journal:  Indian J Crit Care Med       Date:  2022

Review 3.  Advanced Life Support Update.

Authors:  Gavin D Perkins; Jerry P Nolan
Journal:  Crit Care       Date:  2022-03-22       Impact factor: 9.097

4.  Target temperature management versus normothermia without temperature feedback systems for out-of-hospital cardiac arrest survivors.

Authors:  Hui Jai Lee; Jonghwan Shin; Kyoung Min You; Woon Yong Kwon; Kyung Su Kim; You Hwan Jo; Seung Min Park
Journal:  J Int Med Res       Date:  2022-09       Impact factor: 1.573

5.  Target temperature management following cardiac arrest: a systematic review and Bayesian meta-analysis.

Authors:  Anders Aneman; Steven Frost; Michael Parr; Markus B Skrifvars
Journal:  Crit Care       Date:  2022-03-12       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.